Drug
Olopatadine clinical trials
Also written PATADAY®, PATANOL® and AL-4943A.
- studies test it
- 36
- open now
- 0
- in phase 3
- 9
- first study started
- 2000
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
35 studies that test it; most in 2010 (7)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 9
- Phase 4
- 21
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 6
Alcon Research (24) · Andover Research Eye Institute (2) · Allergan (2) · University of Wisconsin, Madison (1) · Vanderbilt University Medical Center (1) · McCabe Vision Center (1) · University of Chicago (1) · Greiner, Jack V., OD DO PhD (1)
Often tested with
Tested in the same studies.
Fluticasone (2) · Alcaftadine (2) · Fluticasone furoate (2) · Loratadine (1) · Dexamethasone (1) · Bepotastine besilate (1) · Tranilast (1) · Epinastine (1)
Studies
Open first, then newest update. How each study uses olopatadine is read from its arms, and is right about nine times in ten.
Testing it · 36
- A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic ConjunctivitisCompletedPhase 4Andover Research Eye InstituteNCT05314621Written as olopatadine hydrochloride ophthalmic solution 0.7%)
- A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic ConjunctivitisCompletedPhase 4Andover Research Eye InstituteNCT05265910Written as olopatadine hydrochloride ophthalmic solution 0.7%
- Effect of Olopatadine on Allergic Tear MediatorsCompletedNot applicableUniversity of Wisconsin, MadisonNCT00609128Written as olopatadine
- Safety of PATANASE Nasal Spray in Patients With Perennial Allergic RhinitisCompletedPhase 4Alcon ResearchNCT00789555Written as Olopatadine hydrochloride 0.6% nasal spray (PATANASE)
- Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese SubjectsCompletedPhase 3Alcon ResearchNCT02322216Written as Olopatadine Hydrochloride Ophthalmic Solution 0.2%
- Safety Study of Olopatadine Nasal SprayCompletedPhase 3Alcon ResearchNCT00578331Written as Olopatadine 0.6% nasal spray
- Olopatadine 0.2% for the Treatment of Allergic ConjunctivitisCompletedPhase 3Alcon ResearchNCT00331500Written as Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- Olopatadine Eye Drops and Allergy Skin TestingCompletedNot applicableVanderbilt University Medical CenterNCT00775658Written as olopatadine
- Patient Perception Study for AL-4943ACompletedPhase 4Alcon ResearchNCT01294969Written as AL-4943A
- Mast-Cell Stabilizing Effects of OlopatadineCompletedPhase 4Alcon ResearchNCT00389025Written as Olopatadine (generic name)
- Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in JapanCompletedPhase 4Alcon ResearchNCT02251613Written as Olopatadine HCl ophthalmic solution, 0.1%
- Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric PatientsCompletedPhase 4Alcon ResearchNCT01109485Written as Olopatadine hydrochloride ophthalmic solution 0.1%
- Safety and Comfort of AL-4943A Ophthalmic SolutionCompletedPhase 1Alcon ResearchNCT01326858Written as Olopatadine hydrochloride ophthalmic solution, 0.7%
- Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis PatientsCompletedPhase 4Alcon ResearchNCT01697969Written as Olopatadine hydrochloride ophthalmic solution, 0.2%
- Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Alcon ResearchNCT01743027Written as AL-4943A ophthalmic solution
- An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic ConjunctivitisCompletedPhase 3Alcon ResearchNCT01037179Written as Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese SubjectsCompletedPhase 3Alcon ResearchNCT00987272Written as Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- A Six-Week Safety Study of an Investigational Ophthalmic SolutionCompletedPhase 3Alcon ResearchNCT01698814Written as AL-4943A Ophthalmic Solution
- Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic ConjunctivitisCompletedPhase 4Alcon ResearchNCT01119287Written as Olopatadine hydrochloride 0.1% ophthalmic solution
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic ConjunctivitisCompletedPhase 4AllerganNCT01732757Written as Olopatadine 0.2%
See all 36 studies that test olopatadine →
Given in every arm · 3 — olopatadine is usual care beside what is tested
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)CompletedPhase 3Merck Sharp & Dohme LLCNCT02478398Written as Olopatadine
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)CompletedPhase 3ALK-Abelló A/SNCT00550550Written as Olopatadine 0.1% Rescue Treatment
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)CompletedPhase 3ALK-Abelló A/SNCT00562159Written as Olopatadine 0.1% Rescue Treatment
As the comparator · 13 — what is tested is compared with olopatadine
- Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic ConjunctivitisCompletedPhase 2Senju USA, Inc.NCT00836485Written as Olopatadine 0.2%
- Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis TreatmentCompletedPhase 4Laboratorios PoenNCT04776096Written as Olopatadine Hydrochloride 0.2% BAK
- Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic ConjunctivitisStatus unknownPhase 4Michael Marchand, MDNCT03186755Written as Olopatadine hydrochloride ophthalmic solution 0.1%
- Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic ConjunctivitisCompletedPhase 2ORA, Inc.NCT03320434Written as Patanol
- DEXTENZA Therapy for Treatment of Allergic ConjunctivitisCompletedPhase 4Clinical Research Center of FloridaNCT04708821Written as olopatadine hydrochloride ophthalmic solution 0.7%
- AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic ConjunctivitisCompletedPhase 3AllerganNCT02161146Written as Olopatadine
- Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic ConjunctivitisWithdrawnPhase 3Laboratorios Sophia S.A de C.V.NCT01657240Written as Olopatadine Hydrochloride
- Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)CompletedPhase 2Glenmark Pharmaceuticals Ltd. IndiaNCT03444506Written as PATANASE nasal spray
- Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic ConjunctivitisCompletedPhase 4Merck Sharp & Dohme LLCNCT00534794Written as Pataday
- Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01363700Written as Olopatadine Hydrochloride 0.1% Ophthalmic Solution
- Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic ConjunctivitisCompletedPhase 2Laboratoires TheaNCT01344083Written as Olopatadine hydrochloride
- Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)CompletedPhase 3Bausch & Lomb IncorporatedNCT01435460Written as Olopatadine 0.1%
- Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic ConjunctivitisCompletedPhase 3AllerganNCT01258309Written as olopatadine hydrochloride 0.1% ophthalmic solution
Codes
What other systems call olopatadine · ClinicalTrials.gg INT006620
- MeSH (NLM) D000069605Olopatadine HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) D27V6190PMOLOPATADINEConfirmed FDA, NLM, Wikidata
- RxNorm 135391Confirmed FDA, Wikidata
- Wikidata Q3267092olopatadineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61866OlopatadineOne source FDA
- DrugBank DB00768One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069605 | Olopatadine Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | D27V6190PM | OLOPATADINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 135391 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3267092 | olopatadine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61866 | Olopatadine | One source FDA |
| DrugBank | DB00768 | — | One source Wikidata |
Also registered as olopatadine hydrochloride (UNII 2XG66W44KF · RxNorm 236599).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.